全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Young-Onset Autoimmune Myasthenia Gravis in a Resource-Limited Setting: A Clinical Case Report

DOI: 10.4236/oalib.1114130, PP. 1-7

Subject Areas: Neurology

Keywords: Myasthenia Gravis, Autoimmune Disease, Electromyography, Corticosteroids, Low-Resource Settings, Case Report

Full-Text   Cite this paper   Add to My Lib

Abstract

Autoimmune Myasthenia Gravis (MG) is rarely reported from low-resource settings, where diagnostic delays and limited therapeutic options remain major challenges. We report a young adult with progressive, fluctuating muscle weakness evolving over three years before diagnosis. In the absence of antibody testing and thoracic imaging, the diagnosis relied on clinical features and electrophysiological confirmation through a reproducible decrement on repetitive nerve stimulation. Corticosteroid therapy resulted in significant clinical improvement despite limited access to pyridostigmine and immunosuppressive agents. This report emphasizes the feasibility of diagnosing and managing myasthenia gravis based primarily on clinical expertise and electrophysiological testing in resource-constrained environments, and underscores the need for strengthened diagnostic capacity and access to essential medications.

Cite this paper

Soumah, C. O. , Diallo, M. T. , Touré, M. L. , Barry, S. D. and Cissé, F. A. (2026). Young-Onset Autoimmune Myasthenia Gravis in a Resource-Limited Setting: A Clinical Case Report. Open Access Library Journal, 13, e14130. doi: http://dx.doi.org/10.4236/oalib.1114130.

References

[1]  Gilhus, N.E. (2016) Myasthenia Gravis. New England Journal of Medicine, 375, 2570-2581. https://doi.org/10.1056/nejmra1602678
[2]  Grob, D., Brunner, N., Namba, T. and Pagala, M. (2008) Lifetime Course of Myasthenia Gravis. Muscle & Nerve, 37, 141-149. https://doi.org/10.1002/mus.20950
[3]  O’Connor, P. and Palace, J. (2021) Myasthenia Gravis. Practical Neurology, 21, 399-408.
[4]  Aarli, J.A. (1989) Myasthenia Gravis in Developing Countries. Acta Neurologica Scandinavica Supplementum, 124, 64-68.
[5]  Stålberg, E.V., Trontelj, J.V. and Sanders, D.B. (2010) Single-Fiber Electromyography. 3rd Edition, Edshagen Publishing House.
[6]  Meriggioli, M.N. and Sanders, D.B. (2009) Autoimmune Myasthenia Gravis: Emerging Clinical and Biological Heterogeneity. The Lancet Neurology, 8, 475-490. https://doi.org/10.1016/s1474-4422(09)70063-8
[7]  Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A. and Vincent, A. (2001) Auto-Antibodies to the Receptor Tyrosine Kinase Musk in Patients with Myasthenia Gravis without Acetylcholine Receptor Antibodies. Nature Medicine, 7, 365-368. https://doi.org/10.1038/85520
[8]  Sanders, D.B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., et al. (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, 96, 114-122. https://doi.org/10.1212/wnl.0000000000011124
[9]  Howard Jr., J.F., Barohn, R.J., Cutter, G.R., et al. (2017) Eculizumab in Refractory Generalized Myasthenia Gravis. The New England Journal of Medicine, 377, 631-639.
[10]  Howard Jr., J.F., Bril, V., Vu, T., et al. (2022) Safety and Efficacy of Ravulizumab in Adults with Generalized Myasthenia Gravis: The Champion-Mg Trial. The Lancet Neurology, 21, 589-600.
[11]  Howard, J.F., Bril, V., Vu, T., Karam, C., Peric, S., Margania, T., et al. (2021) Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Neu-rology, 20, 526-536. https://doi.org/10.1016/s1474-4422(21)00159-9
[12]  Marx, A., Müller‐Hermelink, H.K. and Ströbel, P. (2003) The Role of Thymomas in the Development of Myasthenia Gravis. Annals of the New York Academy of Sciences, 998, 223-236. https://doi.org/10.1196/annals.1254.025
[13]  Wendell, L.C. and Levine, J.M. (2011) Myas-thenic Crisis. The Neurohospitalist, 1, 16-22. https://doi.org/10.1177/1941875210382918
[14]  Mantegazza, R. and An-tozzi, C. (2018) When Myasthenia Gravis Is Deemed Refractory: Clinical Signposts and Treatment Strategies. Therapeutic Advances in Neurological Disorders, 11, Article 1756285617749134.
[15]  Kouassi, B., Napon, C., Kaboré, J., Millogo, A., Assogba, K., et al. (2018) Difficultés diagnostiques de la myasthénie dans les pays à ressources limitées: Expérience ouest-africaine. Revue Neurologique (Paris), 174, 577-582.

Full-Text


Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133